cilengitide has been researched along with arginyl-glycyl-aspartic acid in 11 studies
| Studies (cilengitide) | Trials (cilengitide) | Recent Studies (post-2010) (cilengitide) | Studies (arginyl-glycyl-aspartic acid) | Trials (arginyl-glycyl-aspartic acid) | Recent Studies (post-2010) (arginyl-glycyl-aspartic acid) |
|---|---|---|---|---|---|
| 194 | 29 | 133 | 4,556 | 17 | 1,799 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| De Simone, M; Di Leva, FS; Hegemann, JD; Kessler, H; Knappe, TA; Marahiel, MA; Marinelli, L; Novellino, E; Xie, X; Zahler, S; Zimmermann, M | 1 |
| Arnaout, MA; Frech, M; Goodman, SL; Joachimiak, A; Stehle, T; Xiong, JP; Zhang, R | 1 |
| Achilefu, S; Bloch, S; Chance, B; Dorshow, RB; Liang, K; Markiewicz, MA; Ye, Y; Zhong, T | 1 |
| Auzzas, L; Battistini, L; Belvisi, L; Burreddu, P; Casiraghi, G; Castorina, M; Curti, C; Gaetani, E; Giannini, G; Motto, I; Nicastro, G; Pisano, C; Rassu, G; Zanardi, F | 1 |
| Jiang, FC; Ni, GH | 1 |
| Cai, W; Chen, X | 1 |
| Mikkelsen, T; Nabors, LB; Reardon, DA; Stupp, R | 1 |
| Nabors, LB; Neyns, B; Reardon, DA; Stupp, R; Tonn, JC; Weller, M | 1 |
| Joner, M; Kapp, TG; Kessler, H; Laufer, B; Li, L; Mas-Moruno, C; Neubauer, S; Rechenmacher, F; Steigerwald, K | 1 |
| Byron, SK; Craig, SE; Humphries, MJ; Jowitt, TA; Mould, AP | 1 |
| An, X; Ge, H; Gu, T; Guo, L; Jiang, Q; Meng, X; Ning, X; Shan, X; Zhang, L | 1 |
3 review(s) available for cilengitide and arginyl-glycyl-aspartic acid
| Article | Year |
|---|---|
[Advances in the study of the integrin alpha(v) beta3 antagonists].
Topics: Acetates; Aminopyridines; Angiogenesis Inhibitors; Benzodiazepinones; Humans; Integrin alphaVbeta3; Ligands; Molecular Structure; Oligopeptides; Peptides, Cyclic; Snake Venoms | 2006 |
Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disintegrins; Drug Delivery Systems; Gene Silencing; Gene Targeting; Humans; Integrin alphaVbeta3; Magnetic Resonance Imaging; Neoplasms; Oligopeptides; Positron-Emission Tomography; RNA, Small Interfering; Snake Venoms; Tomography, Emission-Computed, Single-Photon; Ultrasonography | 2006 |
Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme.
Topics: Animals; Antineoplastic Agents; Central Nervous System Neoplasms; Clinical Trials as Topic; Drug Evaluation, Preclinical; Glioblastoma; Humans; Integrins; Models, Molecular; Oligopeptides; Protein Binding; Snake Venoms; Treatment Outcome | 2008 |
8 other study(ies) available for cilengitide and arginyl-glycyl-aspartic acid
| Article | Year |
|---|---|
Rational improvement of the affinity and selectivity of integrin binding of grafted lasso peptides.
Topics: Bacteriocins; Cell Adhesion; Human Umbilical Vein Endothelial Cells; Humans; Integrin alphaVbeta3; Models, Molecular; Molecular Dynamics Simulation; Nuclear Magnetic Resonance, Biomolecular; Peptides; Protein Conformation; Snake Venoms | 2014 |
Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand.
Topics: Amino Acid Sequence; Binding Sites; Crystallography, X-Ray; Ligands; Manganese; Models, Molecular; Oligopeptides; Peptides, Cyclic; Protein Structure, Quaternary; Protein Structure, Secondary; Protein Structure, Tertiary; Receptors, Vitronectin; Snake Venoms | 2002 |
Synergistic effects of light-emitting probes and peptides for targeting and monitoring integrin expression.
Topics: Animals; Carbocyanines; Fluorometry; Integrins; Ligands; Mice; Mice, Nude; Microscopy, Fluorescence; Molecular Probe Techniques; Neoplasms; Oligopeptides; Peptides, Cyclic; Snake Venoms; Spectrophotometry; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 2005 |
Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders.
Topics: Binding, Competitive; Crystallography, X-Ray; Cycloleucine; Integrin alphaVbeta3; Integrins; Models, Molecular; Molecular Structure; Oligopeptides; Peptides, Cyclic; Protein Binding; Radioligand Assay; Receptors, Vitronectin; Snake Venoms; Solutions; Structure-Activity Relationship | 2005 |
Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Industry; Glioblastoma; Humans; Integrins; Oligopeptides; Snake Venoms; Treatment Outcome | 2011 |
The integrin ligand c(RGDf(NMe)Nal) reduces neointimal hyperplasia in a polymer-free drug-eluting stent system.
Topics: Animals; Cell Line; Cell Proliferation; Disease Models, Animal; Drug-Eluting Stents; Hyperplasia; Immunosuppressive Agents; Integrins; Oligopeptides; Polymers; Rabbits; Snake Venoms; Wound Healing | 2014 |
Disruption of integrin-fibronectin complexes by allosteric but not ligand-mimetic inhibitors.
Topics: Allosteric Site; Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Binding Sites; Cells, Cultured; Fibronectins; Humans; Integrin alpha5beta1; Integrin alphaVbeta3; Integrins; Ligands; Multiprotein Complexes; Oligopeptides; Peptide Fragments; Protein Binding; Receptors, Vitronectin; Sf9 Cells; Snake Venoms; Spodoptera | 2014 |
Novel Integrin αvβ3-Specific Ligand for the Sensitive Diagnosis of Glioblastoma.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Gene Knockout Techniques; Glioblastoma; Human Umbilical Vein Endothelial Cells; Humans; Integrin alphaVbeta3; Ligands; Male; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Oligopeptides; Optical Imaging; Protein Binding; Snake Venoms; Transfection; Xenograft Model Antitumor Assays | 2019 |